AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses

Recruiting now · Phase 1

Conditions studied: End Stage Renal Disease

In brief

Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.

Key facts

Study ID
NCT04392206
Run by
Houssam Farres, M.D.
People needed
15
Starts
2020-05-15
Expected to finish
2027-06-01
Last updated by the study team
2026-07-10

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.